Research
Hormonal
GLP-1 receptor agonist medications have the potential to promote marked weight loss.
Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.
StrongSupportsmedium confidence
GLP-1 receptor agonist medications have the potential to promote marked weight loss.
Why this rating
The claim is based on a critical review of existing evidence.
Source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Giorgia Rutigliani et al. · Obesity Reviews · 2026
DOI 10.1111/obr.70148
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →